3.2. Erlotinib and MLN0128 Impact EGFR-Driven GBM Cell Survival by Inhibiting the Tumor-Promoting Pathways p-EGFR, MAPK, and PI3K/AKT/MTOR and Inducing Apoptosis. Here, AKT1 is linked to glioblastoma.